MEIP
MEI Pharma Inc

8,494
Loading...
Loading...
News
all
press releases
MEI Pharma Trades Cash For LTC
MEI Pharma moves a nine‑figure treasury slice into Litecoin and seats the coin’s creator on its board.
Stocktwits·2mo ago
News Placeholder
More News
News Placeholder
MEI Pharma Announces $100M Placement To Initiate Litecoin Treasury Strategy: Retail Cheers Charlie Lee’s Addition To Company Board
MEI Pharma intends to use the funds to acquire the native cryptocurrency of the Litecoin blockchain, commonly referred to as “LTC”, which will serve as the company’s primary treasury reserve asset.
Stocktwits·2mo ago
News Placeholder
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation...
Business Wire·7mo ago
News Placeholder
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and...
Business Wire·10mo ago
News Placeholder
MEI Pharma Reports Fiscal Year End 2024 Cash Position
MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of...
Business Wire·1y ago
News Placeholder
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Companys exclusive financial advisor to assist in its previously announced...
Business Wire·1y ago
News Placeholder
MEI Pharma to Consider Strategic Alternatives
MEI Pharma, Inc. (Nasdaq: MEIP) (the Company) today announced that its Board of Directors has determined unanimously to begin evaluation of the Companys strategic alternatives, including potential...
Business Wire·1y ago
News Placeholder
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
Glancy Prongay & Murray LLP (GPM) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors and officers possible violations of state laws. If you own...
Business Wire·1y ago
News Placeholder
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported...
Business Wire·1y ago
News Placeholder
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported...
Business Wire·1y ago

Latest MEIP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.